Michael Jutovsky, M.D.
Uptown Research Institute, LLC
1021 W. Lawrence Avenue
Chicago, IL 60640

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Alliance Director
Tel. (916) 939-6696
Fax (208) 575-3169
Email: clinicaltrials@alliancesites.com

AFFILIATIONS:

Aurora Chicago Lakeshore Hospital
4840 N Marine Dr
Chicago, IL 60640

Swedish Covenant Hospital
5140 N California Ave
Chicago, IL 60625

Amita St. Francis Hospital
355 Ridge Ave, Evanston
IL 60202

EDUCATION:

1988 Medical Doctor
University of Illinois College of Medicine, Chicago, IL

1984 Bachelor of Arts, Biology
Washington University, St Louis, MO

RESIDENCY:

1988 – 1991 Chief Resident
University of Illinois Family Practice Residency Program

LICENSURE:

Licensed Physician and Surgeon, Illinois 036-080157

CERTIFICATION:

Diplomate – National Board of Medical Examiners
Diplomate – American Board of Family Medicine
Diplomate – American Board of Hospice and Palliative Care

PROFESSIONAL EXPERIENCE:

Principal Investigator, January 2004 – present
Uptown Research Institute, LLC, Chicago, IL

Private Practice, Family Medicine, June 2003 – present
MJ Medical Group, S.C., Chicago, IL

Medical Director, 2002 – present
Ravenswood Physicians Association, Chicago, IL

Private Practice, Family Medicine, April 1999 – May 2003
Michael Jutovsky, M.D., LLC, Chicago, IL

Team Physician, 2000 – 2001
Advocate Hospice, Chicago, IL

Team Physician, 2001 – 2005
Season Hospice, Chicago, IL

Private Practice, Family Medicine, August 1998 – March 1999
Family Alternative Health, Chicago, IL

Clinical Medical Consultant, November 1998 – May 2000
Michael Reese Medical Center, Chicago, IL

Private Practice, Family Medicine, Principal Shareholder August 1993 – July 1998
Family Practice North, SC, Chicago, IL

Clinical Medical Consultant, July 1996 – present
Columbia Chicago Lakeshore Hospital, Chicago, IL

Inpatient Hospice Physician, Medical Director Inpatient Unit, August 1993 – July 1998
Vitas Corporation, Chicago, IL

Clinical Medical Consultant, August 1993 – June 1996
Charter-Barclay Hospital, Chicago, IL

Private Practice, Family Medicine, July 1991 – July 1993
Ravenswood Healthcare Centers, Chicago, IL

PROFESSIONAL EXPERIENCE (*continued*):

Private Practice, Family Medicine, August 1992 – July 1993
Field Medical Group, Chicago, IL

House Physician, Department of OB/GYNE July 1990 – June 1992
Ravenswood Hospital Medical Center, Chicago, IL

Clinical Research – Olfaction/Gustation, 1989
Smell and Taste Research and Treatment Foundation, Chicago, IL

CLINIAL TRIAL EXPERIENCE:

Phase I • Bipolar Disorder • Depression • Diabetes Mellitus
Gout • Hypertension • Post-Traumatic Stress Disorder
Schizophrenia or Schizoaffective Disorder • Tardive Dyskinesia

ADDITIONAL TREATMENT EXPERIENCE:

Asthma • Hospice & Palliative Care
Pediatrics • Women's Health

CLINICAL TRIAL EXPERIENCE:

Phase I

A Phase I Randomized, Open-Label, Parallel, Single-Dose Study to Evaluate the Pharmacokinetic Characteristics of XXX of Two Formulations versus INVEGA SUSTENNA® after Intramuscular Injection in Schizophrenia Patients

A Phase I Study of an XXX Initiation Regimen in Adults with Schizophrenia

Bipolar Disorder

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of XXX Monotherapy in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of XXX Adjunctive to XXX or XXX in the Treatment of Patients with major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder

A Phase III Study to Assess the Long-Term Safety, Tolerability, and Durability of Treatment Effect of XXX in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder

CLINICAL TRIAL EXPERIENCE (*continued*):

A Multi-Center, Randomized, Double-Blind Trial of XXX for the Acute Treatment of Manic Episodes, with or without Mixed Features, in Subjects with a Diagnosis of Bipolar I Disorder

A Multi-Center, Open-Label Trial to Evaluate the Safety and Tolerability of XXX in the Treatment of Subjects with Bipolar I Disorder

Depression

A Phase IIa, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral XXX Versus Placebo in Subjects With Major Depressive Disorder

A Phase III, Multi-Center Study of the Long-Term Safety and Tolerability of XXX for the Adjunctive Treatment of Major Depressive Disorder in Adults Who Have an Inadequate Response to Antidepressant Therapy

A Phase III, Randomized, Double-Blind, Multi-Center, Active-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal XXX Plus and Oral Antidepressant in Adult Subjects with Treatment-Resistant Depression

A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of XXX as Adjunct Therapy in the Maintenance Treatment of Adults with Major Depressive Disorder

A Phase III, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with XXX in Adult Subjects with Major Depressive Disorder

Diabetes

A Randomized, Multi-Center, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of XXX on Renal Endpoints in Adult Subjects with Type 2 Diabetes Mellitus

A Comparison of XXX versus XXX in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with 2 or more Oral Antihyperglycemic Medications: An Open-Label, Randomized Study the XXX Study

Gout

A Multicenter, Randomized, Active-Control, Phase IIIB Study to Evaluate the Cardiovascular Safety of XXX and XXX in Subjects with Gout and Cardiovascular Comorbidities

CLINICAL TRIAL EXPERIENCE (*continued*):

Hypertension

A Phase IIIb, Double-Blind, Randomized, 12-Week Efficacy and Safety Study of the XXX plus XXX Fixed-Dose Combination vs XXX in Subjects with Moderate to Severe Essential Hypertension

A Phase III, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the XXX plus XXX Fixed-Dose Combination vs. XXX Fixed-Dose Combination in Subjects with Essential Hypertension

Post-Traumatic Stress Disorder

A Phase III, Double-Blind, Randomized, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX Taken Daily at Bedtime in Patients with Military-Related PTSD

Schizophrenia or Schizoaffective Disorder

A Phase IIIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects with Schizophrenia Treated Prospectively for 6-months with XXX

A Phase IIIb, Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects with Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment with XXX Long-Acting Injection or Oral Antipsychotics

Safety and Tolerability of Initiating XXX in Subjects with Schizophrenia who are Inadequately Treated with XXX or XXX Long Acting Injection

A Phase II, Efficacy, Safety, and Tolerability Study of XXX in Schizophrenia with Alcohol Use Disorder

A Phase III Study to Evaluate Weight Gain of XXX compared to XXX in Adults with Schizophrenia

A Phase III, Multicenter Study to Assess the Long-Term Safety and Tolerability of XXX in Subjects with Schizophrenia

A Phase III Study to Determine the Antipsychotic Efficacy and Safety of XXX in Adult Subjects with Acute Exacerbation of Schizophrenia

A Phase III, Multicenter Study to Assess the Long-Term Safety and Tolerability of XXX in Subjects with Schizophrenia

CLINICAL TRIAL EXPERIENCE (*continued*):

A Randomized, Open-Label, Parallel Design, Multiple-Dose, Comparative Bioequivalence Study of XXX Extended-Release Injectable Suspension (156mg/1.0mL) Versus XXX Extended-Release Injectable Suspension (156mg/1.0mL) in Schizophrenia Patients Already Stabilized on XXX

A One-Year, Open-Label, Study to Evaluate the Safety and Tolerability of XXX Implants as a Maintenance Treatment in Patients with Schizophrenia

Interventional, Randomized, Double-Blind, Active-Controlled, Fixed-Dose Study of XXX in Patients with Schizophrenia

Interventional, Open-Label, Flexible-Dose, Long-Term Safety Study of XXX in Adult Patients with Schizophrenia

A Double-blind, Randomized, Active-controlled, Parallel-group Study of XXX 6-Month Formulation

A Phase IIb/III, Multi-center, Prospective, Randomized, Placebo-controlled, Sequential Parallel Comparison Design (SPCD) Study of the Safety and Efficacy of XXX , a D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adults

An adaptive Phase II/III, Double-blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of XXX , a D-Amino Acid Oxidase Inhibitor, as an Add-on Therapy with XXX, for Residual Symptoms of Refractory Schizophrenia in Adults

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of XXX Extended-Release Injectable Suspension XXX for Subcutaneous Use as Maintenance Treatment in Adult Patients with Schizophrenia

A Phase IIIb, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of XXX or XXX for the Treatment of Schizophrenia in Subjects Hospitalized for Acute Exacerbation

A Randomized, Crossover, Open-Label, Multiple Dose, Pivotal Pharmacokinetic Bioequivalence Study Comparing XXX extended-release IM 156 mg/1.0 mL (100 mg eq) with XXX in Subjects with Schizophrenia or Schizoaffective Disorder

A Pivotal, Multiple-Dose, Pharmacokinetic Bioequivalence Trial Comparing Generic to Reference XXX Extended-Release Injectable Suspension (156 mg/1.0 mL) in Patients with Schizophrenia or Schizoaffective Disorder

CLINICAL TRIAL EXPERIENCE (*continued*):

A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Monotherapy, 12-Week Study to Evaluate the Efficacy and Safety of 2 Fixed Doses of XXX in Adult Patients with Negative Symptoms of Schizophrenia, Followed by 40-Week Open-Label Extension

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of XXX Once Daily Over a 12-Week Treatment Period in Patients with Schizophrenia

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of XXX as Add-On Treatment for Cognitive Impairment in Subjects with Schizophrenia on Stable Doses of Antipsychotic Medication

Tardive Dyskinesia

A Phase III, Open-Label, Safety and Tolerability Study of XXX for the Treatment of Tardive Dyskinesia

An Open-Label, Rollover Study for Continuing XXX Administration for the Treatment of Tardive Dyskinesia

COMMITTEE APPOINTMENTS:

University of Chicago Health Systems Ethics Committee
Ravenswood Hospital Care Council
Weiss PHO Professional Practice Committee
Medical Records Committee
Infection Control Committee
CME/Curriculum Subcommittee – Medical Education
Collaborative Care Committee
Code 99 Review Committee
Advocate PHO Advisory Committee
Ravenswood Physician Association
    Board of Directors, 1991 – 1999, 2002 – Present
    Treasurer, 1995 – 1999
TAP Committee
Medicine Agenda Committee
Ravenswood Hospital Medical Executive Committee:
    Board of Directors 1999 – 2003

ACADEMIC APPOINTMENTS:

Clinical Assistant Professor, Department of Family Medicine
University of Illinois at Chicago College of Medicine

PROFESSIONAL SOCIETIES:

American Academy of Family Physicians
Illinois Academy of Family Physicians
Illinois State Medical Society

AWARDS AND HONORS:

"My Ravenswood Doctor", Physicians Recognition Award, 1990, 1993

PRESENTATIONS AND PUBLICATIONS:

Association for Chemoreception Sciences, "*Study of Gustation and Olfaction in Culinary Experts*", Sarasota, Florida, April 1989.